Class Of Warrant Or Right, Exercise Period

No definition available.

Name:	asrt_ClassOfWarrantOrRightExercisePeriod
Namespace Prefix:	asrt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Class Of Warrant Or Right, Issued During Period

+ References

No definition available.

+ Details

Name:	asrt_ClassOfWarrantOrRightIssuedDuringPeriod
Namespace Prefix:	asrt_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Commercialization Agreement, Net Annual Sales Threshold

+ References

No definition available.

+ Details

Name:	asrt_CommercializationAgreementNetAnnualSalesThreshold
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Commercialization Agreement, Termination, Net Sales Threshold

+ References

No definition available.

+ Details

Name:	asrt_CommercializationAgreementTerminationNetSalesThreshold
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Contract Termination Fee, Cancellation Prior To Agreed Upon Date

+ References

No definition available.

+ Details

Name:	asrt_ContractTerminationFeeCancellationPriorToAgreedUponDate
Namespace Prefix:	asrt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the percentage of royalty on annual net sales.

+ References

No definition available.

+ Details

Name:	asrt_PercentageOfRoyaltyOnAnnualNetSales
Namespace Prefix:	asrt_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Royalty Agreement, Number Of Days After Which Obligation To maintain Standby Letter Of Credit Will Expire

+ References

No definition available.

+ Details

Name:	asrt_RoyaltyAgreementNumberOfDaysAfterWhichObligationTomaintainStandbyLetterOfCreditWillExpire
Namespace Prefix:	asrt_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Arrangement, Annual Payments, Term

+ References

No definition available.

+ Details

Name:	asrt_RoyaltyArrangementAnnualPaymentsTerm
Namespace Prefix:	asrt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Arrangement, Quarterly Payments, Term

+ References

No definition available.

+ Details

Name:	asrt_RoyaltyArrangementQuarterlyPaymentsTerm
Namespace Prefix:	asrt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Arrangement, Termination Period

+ References

No definition available.

+ Details

Name:	asrt_RoyaltyArrangementTerminationPeriod
Namespace Prefix:	asrt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name:	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_CommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=asrt_CollegiumPharmaceuticalIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=asrt_CollegiumPharmaceuticalIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_CommercializationAgreement65RoyaltyOnNetAnnualSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_CommercializationAgreement14RoyaltyOnNetAnnualSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_CommercializationAgreement58RoyaltyOnNetAnnualSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_CommercializationAgreement20RoyaltyOnNetAnnualSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_CommercializationAgreement15RoyaltyOnNetAnnualSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_CommercializationAgreement25RoyaltyOnNetAnnualSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=asrt_CommercializationAgreement17.5RoyaltyOnNetAnnualSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

SUBSEQUENT EVENTS (Details)			12 Months Ended		36 Months Ended
SUBSEQUENT EVENTS (Details)	Jan. 01, 2022 USD ($)	Nov. 08, 2018 USD ($) business_day $ / shares shares	Dec. 31, 2021 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2021 USD ($)
Commercialization agreement, net \| Collegium Pharmaceutical Inc \| Forecast
Subsequent Event [Line Items]
Agreement termination period	12 months		12 months
Net revenue threshold				$ 132,000,000
Period for annual payments to be made	60 days				60 days
Commercialization agreement, net \| Collegium Pharmaceutical Inc \| Forecast \| Product sales, net
Subsequent Event [Line Items]
Net revenues threshold (less than)	$ 170,000,000		$ 180,000,000
Commercialization Agreement, 65% Royalty on Net Annual Sales \| Collegium Pharmaceutical Inc \| Forecast
Subsequent Event [Line Items]
Percentage of royalty on annual net sales			65.00%		65.00%
Net revenue threshold					$ 180,000,000
Commercialization Agreement, 14% Royalty on Net Annual Sales \| Collegium Pharmaceutical Inc \| Forecast
Subsequent Event [Line Items]
Percentage of royalty on annual net sales			14.00%		14.00%
Commercialization Agreement, 14% Royalty on Net Annual Sales \| Collegium Pharmaceutical Inc \| Forecast \| Minimum
Subsequent Event [Line Items]
Net revenue threshold					$ 180,000,000
Commercialization Agreement, 14% Royalty on Net Annual Sales \| Collegium Pharmaceutical Inc \| Forecast \| Maximum
Subsequent Event [Line Items]
Net revenue threshold					$ 210,000,000
Commercialization Agreement, 58% Royalty on Net Annual Sales \| Collegium Pharmaceutical Inc \| Forecast
Subsequent Event [Line Items]
Percentage of royalty on annual net sales	58.00%		58.00%		58.00%
Net revenue threshold	$ 233,000,000
Commercialization Agreement, 58% Royalty on Net Annual Sales \| Collegium Pharmaceutical Inc \| Forecast \| Minimum
Subsequent Event [Line Items]
Net revenue threshold					$ 210,000,000
Commercialization Agreement, 58% Royalty on Net Annual Sales \| Collegium Pharmaceutical Inc \| Forecast \| Maximum
Subsequent Event [Line Items]
Net revenue threshold					$ 233,000,000
Period for quarterly payments to be made	45 days
Commercialization Agreement, 20% Royalty on Net Annual Sales \| Collegium Pharmaceutical Inc \| Forecast
Subsequent Event [Line Items]
Percentage of royalty on annual net sales			20.00%		20.00%
Commercialization Agreement, 20% Royalty on Net Annual Sales \| Collegium Pharmaceutical Inc \| Forecast \| Minimum
Subsequent Event [Line Items]
Net revenue threshold					$ 233,000,000
Commercialization Agreement, 20% Royalty on Net Annual Sales \| Collegium Pharmaceutical Inc \| Forecast \| Maximum
Subsequent Event [Line Items]
Net revenue threshold					$ 258,000,000
Commercialization Agreement, 15% Royalty on Net Annual Sales \| Collegium Pharmaceutical Inc \| Forecast
Subsequent Event [Line Items]
Percentage of royalty on annual net sales			15.00%		15.00%
Net revenue threshold					$ 258,000,000
Commercialization Agreement, 25% Royalty on Net Annual Sales \| Collegium Pharmaceutical Inc \| Forecast
Subsequent Event [Line Items]
Percentage of royalty on annual net sales	25.00%
Commercialization Agreement, 25% Royalty on Net Annual Sales \| Collegium Pharmaceutical Inc \| Forecast \| Minimum
Subsequent Event [Line Items]
Net revenue threshold	$ 233,000,000
Commercialization Agreement, 25% Royalty on Net Annual Sales \| Collegium Pharmaceutical Inc \| Forecast \| Maximum
Subsequent Event [Line Items]
Net revenue threshold	$ 258,000,000
Commercialization Agreement, 17.5% Royalty on Net Annual Sales \| Collegium Pharmaceutical Inc \| Forecast
Subsequent Event [Line Items]
Percentage of royalty on annual net sales	17.50%
Net revenue threshold	$ 258,000,000
Subsequent Event \| Commercialization agreement, net \| Collegium Pharmaceutical Inc
Subsequent Event [Line Items]
Agreement termination period		60 days
Contract termination fee		$ 5,000,000
Subsequent Event \| Commercialization agreement, net \| Collegium Pharmaceutical Inc
Subsequent Event [Line Items]
Agreement termination period		12 months
Warrant issued during period (in shares) \| shares		1,041,667
Warrant exercise price (in dollars per share) \| $ / shares		$ 19.20
Warrant exercise period		4 years
Number of days after which obligation to maintain standby letter of credit will expire (business day) \| business_day		1